Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.
Glutamate is probably the most important excitatory neurotransmitter in the brain. The glutamate N-methyl-D-aspartate receptor (NMDAR) is a calcium-gated channel that coordinates with G protein-coupled receptors (GPCRs) to establish the efficiency of the synaptic transmission. Cross-regulation between these receptors requires the concerted activity of the histidine triad nucleotide-binding protein 1 (HINT1) and of the sigma receptor type 1 (σ1R). Essential brain functions like learning, memory formation and consolidation, mood and behavioral responses to exogenous stimuli depend on the activity of NMDARs. In this biological context, endocannabinoids are released to retain NMDAR activity within physiological limits. The efficacy of such control depends on HINT1/σ1R assisting in the physical coupling between cannabinoid type 1 receptors (CB1Rs) and NMDARs to dampen their activity. Subsequently, the calcium-regulated HINT1/σ1R protein tandem uncouples CB1Rs to prevent NMDAR hypofunction. Thus, early recruitment or a disproportionate cannabinoid induced response can bring about excess dampening of NMDAR activity, impeding its adequate integration with GPCR signaling. Alternatively, this control circuit can apparently be overridden in situations where bursts of NMDAR overactivity provoke convulsive syndromes. In this review we will discuss the possible relevance of the HINT1/σ1R tandem and its use by endocannabinoids to diminish NMDAR activity and their implications in psychosis/schizophrenia, as well as in NMDAR-mediated convulsive episodes.
Department of Molecular, Cellular and Developmental Neurobiology, Laboratory of Neuropharmacology, Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
María
M
Rodríguez-Muñoz
Department of Molecular, Cellular and Developmental Neurobiology, Laboratory of Neuropharmacology, Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Pilar
P
Sánchez-Blázquez
Drug Discovery & Preclinical Development, Esteve, Barcelona, Spain.
Manuel
M
Merlos
Department of Molecular, Cellular and Developmental Neurobiology, Laboratory of Neuropharmacology, Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Javier
J
Garzón-Niño
D000818:Animals; D002186:Cannabinoids / Q000627:therapeutic use; D063388:Endocannabinoids / Q000502:physiology*; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D020239:Receptor Cross-Talk; D043884:Receptor, Cannabinoid, CB1 / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy
D002186:Cannabinoids; D063388:Endocannabinoids; D043884:Receptor, Cannabinoid, CB1; D043562:Receptors, G-Protein-Coupled; D016194:Receptors, N-Methyl-D-Aspartate
GPCR-NMDAR coordination; HINT1 protein; convulsive disorders; mood disorders; σ1R